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Byproducts of cytokine activation are sometimes useful as surrogate biomarkers for monitoring cytokine generation
in patients. Transforming growth factor (TGF)-β plays a pivotal role in pathogenesis of hepatic fibrosis. TGF-β is
produced as part of an inactive latent complex, in which the cytokine is trapped by its propeptide, the
latency-associated protein (LAP). Therefore, to exert its biological activity, TGF-β must be released from the latent
complex. Several proteases activate latent TGF-β by cutting LAP. We previously reported that Camostat Mesilate, a
broad spectrum protease inhibitor, which is especially potent at inhibiting plasma kallikrein (PLK), prevented liver
fibrosis in the porcine serum-induced liver fibrosis model in rats. We suggested that PLK may work as an activator
of latent TGF-β during the pathogenesis of liver diseases in the animal models. However, it remained to be
elucidated whether this activation mechanism also functions in fibrotic liver in patients.
Here, we report that PLK cleaves LAP between R58 and L59 residues. We have produced monoclonal antibodies
against two degradation products of LAP (LAP-DP) by PLK, and we have used these specific antibodies to
immunostain LAP-DP in liver tissues from both fibrotic animals and patients.
The N-terminal side LAP-DP ending at R58 (R58 LAP-DP) was detected in liver tissues, while the C-terminal side
LAP-DP beginning at L59 (L59 LAP-DP) was not detectable. The R58 LAP-DP was seen mostly in α-smooth muscle
actin-positive activated stellate cells.
These data suggest for the first time that the occurrence of a PLK-dependent TGF-β activation reaction in patients
and indicates that the LAP-DP may be useful as a surrogate marker reflecting PLK-dependent TGF-β activation in
fibrotic liver both in animal models and in patients.
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Liver fibrosis is characterized as the pathological deposition
of excessive extracellular matrix (ECM), which finally
causes hepatic dysfunction (Bataller and Brenner 2005). A
key driver of fibrosis is the 25 kD homodimeric cytokine,
transforming growth factor (TGF)-β (Dooley and ten Dijke
2012). TGF-β is produced as a latent complex; therefore, an
essential step for controlling TGF-β activity is its acti-
vation, a process in which biologically active TGF-β is* Correspondence: skojima@riken.jp
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in any medium, provided the original work is preleased from the latent complex (Figure 1a) (Dabovic
and Rifkin 2008).
TGF-β1 is produced as a 390 amino acid precursor
protein consisting of a signal peptide of 29 amino acids,
an N-terminal pro-region called latency-associated protein
(LAP), and a C-terminal region that becomes the active
TGF-β1 molecule, and each region dimerized through
S-S bonds. After processing by cleavage at R278-A279 by
a furin-like protease, the LAP non-covalently binds the
mature TGF-β1, forming small latent complex (SLC)
and preventing active TGF-β1 from binding its cognate
receptors (Figure 1a). The active TGF-β1 and the LAP
homodimer are 25 kD and 75 kD, respectively. The
SLC is S-S bonded to another gene product, the latentOpen Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
Figure 1 Determination of the LAP cleavage site produced during PLK-dependent TGF-β activation. (a) Schematic depiction of latent
TGF-β1 activation by PLK. PLK cleaves LAP between R58 and L59 residues, which may destroy the interaction between LAP and active TGF-β1
molecule, releasing active TGF-β1 from the latent complex. LLC; large latent complex, SLC; small latent complex, LTBP; latent TGF-β binding protein.
(b) The PLK cleavage site was determined by amino acid sequencing of LAP-DP isolated after SDS-PAGE. The amino acid sequences around the PLK
cleavage site are illustrated. Antibodies (Ab), which specifically recognize cutting edges of LAP-DPs, were produced. White “Y” represents R58 antibody
recognizing the N-terminal side R58 LAP-DP, whereas black “Y” represents L59 antibody recognizing the C-terminal side L59 LAP-DP.
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the large latent complex (LLC). This complex can be se-
questered in the ECM (Figure 1a) (Breitkopf et al. 2001).
LTBP is a member of an ECM protein family, fibrillin
(Zilberberg et al. 2012).
Several molecules are known to activate TGF-β1 in
animal models. These include integrins (Nishimura 2009;
Henderson et al. 2013), thrombospondin (Ribeiro et al.
1999), and proteases, such as matrix metalloproteinases
(MMPs) (Yu and Stamenkovic 2000) and serine proteases
(Jenkins 2008). Lyons R.M. et al. first reported that plasmin
digests LAP and activates TGF-β1 in vitro (Lyons et al.
1990). Using a protease inhibitor, Camostat Mesilate, we
previously demonstrated that plasma kallikrein (PLK) is
involved in the TGF-β1 activation associated with liver
fibrosis and impaired liver regeneration in animal models
(Okuno et al. 2001; Akita et al. 2002). However, it remained
to be elucidated whether PLK-dependent TGF-β1 acti-
vation also occurs during the pathogenesis of liver fibrosis
in patients.
In this paper, we describe successful experiments
aimed at generating specific antibodies against the two
degradation products of LAP (LAP-DP) produced after
PLK digestion, and the use of these antibodies to stain
the LAP-DP in patient livers, thereby providing evidence
of PLK-dependent TGF-β1 activation in human hepatic
fibrosis. The results demonstrate the potential utility of
the LAP-DP as a surrogate marker for PLK-dependent
activation of TGF-β1 in the liver.Results
Identification of LAP cleavage sites during proteolytic
activation of latent TGF-β1
PLK primarily cleaved recombinant human LAP β1
(rhLAP β1) between R58 and L59 residues (Figure 1b).
Further incubation resulted in cleavage between R267and
A268 residues.
Preparation of specific antibodies that recognize LAP
neo-epitopes formed by PLK during TGF-β1 activation
Based on the amino acid sequences of PLK cleavage site,
we prepared monoclonal antibodies that recognized the
neo-epitopes formed within LAP during PLK-dependent
TGF-β1 activation (Figure 1). The antibodies against
the neo-C-terminal end of the PLK-cleaved N-terminal
side LAP-DP ending at R58 (referred as R58 LAP-DP) and
the neo-N-terminal end of the PLK-cleaved C-terminal side
LAP-DP beginning from L59 (referred as L59 LAP-DP)
were named R58 and L59 antibodies, respectively. Figure 2
shows Western blots using Glutathione-S-transferase (GST)
fused-recombinant human latent TGF-β1 (GST-rhLTGF-
β1) or rhLAP β1 (schematic structures are illustrated
in panel a) to examine the specificities of R58 and L59
antibodies. The R58 antibody recognized only GST-
fused R58 LAP-DP around 30 kD (panel b, lane 2), and
the L59 antibody recognized the 29 kD of L59 LAP-DP
(panel d, lane 2). However, both R58 and L59 antibodies
did not recognize uncleaved GST-rhLTGF-β1 and rhLAP
β1 (panels b and d, lane 1) that were detectable by the
Figure 2 Specificity of R58 and L59 antibodies. (a) Schematic structure of a GST- rhLTGF-β1 protein generated in bacteria and a commercial
rhLAP β1 generated in insect cells. The PLK cleavage site is indicated by arrowhead. (b-e) GST-LTGF-β1/rhLAP β1was incubated with/without PLK
or PLN for 45 min at 37°C, and thereafter equal amounts of samples containing either 50 ng GST-rhLTGF-β1 or 500 ng rhLAP β1 were subjected
to each lane in SDS-PAGE under reducing conditions followed by Western blot analyses using R58/L59 antibodies (b, d, respectively). Membranes
used in panels b and d were reprobed with monoclonal (c) or polyclonal (e) anti-LAP antibodies. Lanes 1, intact GST-rhLTGF-β1 or rhLAP-β1; lanes 2,
PLK digested GST-rhLTGF-β1 or rhLAP-β1; lanes 3, PLK; lane 4, PLN digested GST-rhLTGF-β1 or rhLAP-β1; lane 5, PLN. Representative results from three
independent experiments with a similar result are shown.
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side LAP-DP (panel c) or the polyclonal anti-LAP antibody
recognizing C-terminal side LAP-DP (panel e). Moreover,
neither R58 nor L59 antibodies detected LAP-DPs gen-
erated by plasmin (PLN) digestion (panels b and d, lane 4)
These data demonstrated that the anti-LAP antibodies
recognize both LAP and PLK-cleaved LAP-DP, while
the R58 and L59 antibodies specifically recognize only
the respective LAP-DP. There are three isoforms of
pro-TGF-βs. Amino acid sequences between E47 and
L59 residues in LAP are identical between TGF-β1 and
TGF-β3 (Additional file 1: Figure S1). Hence, we checked
whether R58 antibody can recognize TGF-β3 LAP-DP as
well as TGF-β1 LAP. As shown in Additional file 2: Figure
S2, R58 antibody recognized PLK-digested TGF-β1 and β3
LAP peptide, but not non-digested and PLN-digested TGF-
β1 and β3 LAP peptides (upper and lower lane, respectively)
nor TGF-β2 LAP peptide, which does not have P1 site R58
residue, irrespective of PLK or PLN digestion (middle lane).
These data suggested that R58 and L59 antibodies are
promising tools to monitor cleavage of LAP by PLK, in
other words, both R58 and L59 LAP-DPs can be footprints
of PLK-dependent TGF-β1 as well as TGF-β3 activation.
Immunohistochemistry of murine fibrotic liver using
R58 antibodies
Because LAP may be S-S bonded to LTBP present in the
ECM, we expected that the R58 LAP-DP would remain
within fibrotic tissues after cleavage of LAP by PLK. We
tested this possibility in fibrotic livers from the carbon
tetrachloride (CCl4)-treated mice and bile duct ligated
(BDL)-mice using R58 antibody. As shown in Figure 3, at
12 weeks after initiating CCl4 treatment, CCl4-treated mice
displayed hepatocellular injury around the lobes (panel a)
and bridging fibrosis from central veins to portal areas
(panel b). The R58 LAP-DP was detectable and increased
in CCl4-treated mice (panel c), especially along fibrotic
areas in CCl4-treated mice compared with olive oil treated
control mice. Positive area rates were increased 5-folds as
written underneath panels c and f. Small positive spots seen
in the control section were non-specific staining of mostly
erythrocytes (panel f ). Similar results were obtained
from BDL mice (Figure 4). BDL mice often exhibited
granulomatous lesions (panel a), in which fibroblastic
cells infiltrated and started ECM production (panel b).
The R58 LAP-DP was detected in granulomatous lesions
prior to Sirius red positivity, namely before collagen
accumulation (arrowheads in panel c). Positive areas
were increased 3-folds as written underneath panels c
and f. Signals from R58 LAP-DP was absorbed by pre-
incubation of R58 antibody with antigen-peptides,
and non-immune mouse IgG failed to yield a signal
(Figure 5a-c), indicating that the signals were specific to
R58 LAP-DP. We were unable to stain the L59 LAP-DPwith L59 antibody although various antigen unmasking
procedures were treated (Figure 5d). In, Figure 6, non-
parenchymal regions were recognized by antibody R58
(red arrowheads in upper panels), and mostly overlapped
with α-smooth muscle actin (αSMA)-positive activated
hepatic stellate cells (HSCs) (red arrowheads in second
row panels), but not with CD31-positive liver sinusoidal
endothelial cells (third row panels) nor with F4/80-positive
Kupffer cells (hepatic macrophages) (lower panels).
Activated HSCs in the fibrotic liver were stained strongly
with anti-pSmad3C antibody compared to olive oil-treated
control mice (arrowheads in Figure 7, left panel), suggesting
that TGF-β signaling was provoked. These data suggest
that PLK-dependent TGF-β1/3 activation was induced
in murine liver fibrosis models and that R58 LAP-DP,
but not L59 LAP-DP, can be a footprint of the generation
of active TGF-β1/3 in liver tissue.
Immunohistochemistry of fibrotic liver tissues from
patients using R58 antibody
Finally, we evaluated human liver sections with the R58
antibody to determine if PLK-dependent TGF-β1/3 activa-
tion occurs in clinical liver diseases. Fibrotic liver tissues
from patients with viral hepatitis categorized as A1F2
and A2F2 were stained robustly with the R58 antibody
(Figure 8a). As with animal models, no signals could be
detected by L59 antibody (Figure 8b). In peri-sinusoidal
and fibrotic regions around the hepatic lobes, R58 LAP-DP
was present in non-parenchymal cells, mainly in αSMA-
positive HSC (arrows in Figure 8c). R58 signals could be
detected along fibrous septa, implying that R58 LAP-DP
accumulated within the ECM upon TGF-β1/3 activation.
A similar staining with the R58 antibody was observed
in patients with non-viral hepatitis, such as autoimmune
hepatitis (AIH) and non-alcoholic steatohepatitis (NASH)
(Figure 8d). These data clearly indicated that PLK-dependent
TGF-β1/3 activation is induced during the pathogenesis
of liver fibrosis in patients with a range of liver diseases,
and that PLK-cleaved R58 LAP-DP might serve as a novel
surrogate biomarker of TGF-β1/3 activation and its asso-
ciated fibrosis in patients.
Discussion
An important step to control biological activity of
TGF-β is its activation referred as “TGF-β activation.”
Proteolytic activation of latent TGF-β1 was first de-
scribed in 1988 (Lyons et al. 1988) and was demon-
strated in hepatic stellate cells during the pathogenesis
of liver fibrosis and/or impaired liver regeneration in
animal models (Okuno et al. 2001; Akita et al. 2002).
Although we described PLK-dependent TGF-β activa-
tion in rodent models of the liver diseases, it remained
to be elucidated whether this mechanism is also effective
in patients.
Figure 3 Immunohistochemistry of R58 LAP-DP in fibrotic liver tissues in CCl4-treated mice using R58 antibody. Liver tissues from
CCl4-treated and control (olive oil administrated) mice were stained by HE (a, d) and Sirius Red (b, e), and then immunostained with R58
antibody (c, f). Scale bar = 50 μm. The percentage of fibrotic regions and R58 positive areas were calculated from three fields each from five
sections (5 mice) (total 15 fields) and described as average ± SE under the corresponding panels. A total of 16 mice were evaluated and
representative results are shown.
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LAP of latent TGF-β1, and have generated antibodies
that specifically recognize the neo C- and N-termini of
LAP-DPs (R58 and L59 antibodies, respectively) (Figure 1).
These antibodies may be powerful tools to detect the
footprints of latent TGF-β1 activation. Notably, we suc-
cessfully used the antibodies to detect LAP-DP generatedFigure 4 Immunohistochemistry of R58 LAP-DP in fibrotic liver tissues
sham-operated mice were stained by HE (a, d) and Sirius Red (b, e), and th
percentage of fibrotic regions and R58 positive areas were calculated from
described as average ± SE under the corresponding panels. A total of 16 mduring TGF-β1 activation in human samples. For the first
time, we demonstrated that the PLK-dependent activa-
tion of latent TGF-β1 is associated with human hepatic
diseases with the use of the R58 antibody. This tech-
nique can be generally applied to measure activation of
other cytokines, in which by-products corresponding
to the LAP-DP are generated.in BDL mice using R58 antibody. Liver tissues from BDL and
en immunostained with R58 antibody (c, f). Scale bar = 50 μm. The
three fields each from five sections (5 mice) (total 15 fields) and
ice were evaluated and representative results are shown.
Figure 5 Control experiments for immunostaining with R58 and L59 antibodies. Serial liver sections of from CCl4-treated mice at 12 weeks
were stained with R58 antibody (1 μg/ml) (a), R58 antibody (1 μg/ml) that had been pre-incubated with 10 μg/ml R58 antigen peptide (b), the
same concentration of nonimmune mouse IgG (c), and L59 antibody (1 μg/ml) (d). Scale bars = 25 μm. This picture shows the representative
result from three independent experiments.
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R58-L59 (Figure 1b). Interestingly, the PLK cleavage site
is proximal with the putative binding site for thrombos-
pondin (L54SKL57) (Ribeiro et al. 1999). This suggests
that the region containing L54SKLRL59 is important for
maintaining TGF-β1 latency. Consistent with this idea, it
was recently revealed that the active TGF-β1 molecule is
associated with this region based both on mutational
analysis (Walton et al. 2010) and the crystal structure of
porcine latent TGF-β1 (Shi et al. 2011). Specifically, this
sequence is located near the C-terminal end of α1 helix of
LAP and hydrophobic residues containing L54, L57, and
L59, which are present along the inner face of the α1 helix,
interact with W308/W310 and with aliphatic side chains of
active TGF-β1. The α1 helix is predicted to play a role of a
‘straitjacket’ for active TGF-β1 (Walton et al. 2010). The K56
fastens the C-terminal end of the α1 helix in cooperation
with Y74-A76, and moreover associates S380 via hydrogen
bonding (Shi et al. 2011). The P1 site amino acids (R58) are
located on the outer face of LAP, so PLK cleavage site
should be highly accessible. Proteolytic cleavage within
this region is likely to cause a conformational change
of the LAP, resulting in a loss of its association with
the active TGF-β1 molecule and release of active TGF-β1
molecule from the latent complex.
In Figure 2, we made monoclonal antibodies against
both N- and C-terminal side LAP-DP (R58/L59 LAP-DP)
and checked their reaction specificities by western blotting.R58/L59 antibodies detected neither uncleaved LAP nor
PLN-cleaved LAP-DP, and specifically recognized only PLK-
cleaved LAP-DP, whereas anti-LAP antibodies recognized
both uncleaved and PLK-cleaved LAP-DP. In Figure 2c,
lane 4, we failed to detect N-terminal side LAP-DP made
by PLN digestion with monoclonal anti-LAP antibody that
nicely detected N-terminal side LAP-DP made by PLK di-
gestion. We speculate that the epitope recognized by this
anti-LAP antibody would be lost by PLN digestion.
Three isoforms of proTGF-β (β1-β3) have been char-
acterized (Massague 1990), and LAP domains of differ-
ent isoforms share 28-45% identity. TGF-β2 LAP does
not have the sequences cleaved by PLK, whereas TGF-β3
LAP has the same sequences as TGF-β1 LAP. Our results
indicated that PLK can cleave TGF-β3 LAP, and that their
degradation products were detectable by R58 antibody.
Because TGF-β3 expression is reported to be very weak in
the liver (De Bleser et al. 1997), we think it is likely that the
R58 LAP-DP we detected is derived mainly from TGF-β1
LAP, but partly from TGF-β3 LAP.
We also successfully detected PLK-cleaved R58 LAP-DP
using the R58 antibody in fibrotic mice, suggesting that
PLK dependent TGF-β1/3 activation was at least involved
in murine hepatic fibrosis and that PLK-cleaved LAP-DP
might be a marker for liver fibrosis. Our previous study
demonstrated that PLN also plays an important role in liver
fibrosis in the rat porcine serum model (Okuno et al. 2001),
therefore we are now using the same strategy to produce
Figure 6 Identification of R58 positive cells in CCl4-treated mice liver sections. Paraffin serial sections were immunostained with, R58
(upper panels), anti-αSMA (second row panels), anti-CD31 (third row panels), and anti-F4/80 (lower panels) antibodies. R58 positive signals were
compared with αSMA, CD31, or F4/80 signals in same areas of each sections. The red arrowheads (R58 and αSMA panels) represent respectively
both R58 and αSMA positive cells along with fibrotic septa. Scale bar = 50 μm.
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to murine models, R58 LAP-DP was observed in patients
suffering from hepatic diseases. Fibrous septa were obvi-
ously stained by the R58 antibody, indicating that R58
LAP-DP was generated at the site of the TGF-β1/3 activa-
tion and remained there. The intensity of R58 signals did
not correlate with the severity of hepatic inflammation and
fibrosis, so future studies will assess what drives increased
R58 expression in vivo.
In contrast to the R58 antibody, we obtained essentially
no positive signals with L59 antibody staining in both
rodent and human samples. This suggests that C-terminal
side L59 LAP-DP might be released after proteolytic di-
gestion. Recently, we established an ELISA using the
L59 antibody and successfully detected PLK-cleaved
L59 LAP-DP generated in in vitro reactions. Currently,we are examining if we can detect L59 LAP-DP in plasma
from animal models and patients, and if so, what is the
clinical relevance of these values in liver diseases.
Integrins are known to activate TGF-β1, and it is reported
that several subtypes of integrin, for example, αvβ6, are
related to hepatic fibrosis in both animal models and
patients (Patsenker et al. 2008; Henderson and Sheppard
2013; Allison 2012). Because integrins, which are anchored
to the cell membrane, stretch the LAP by interacting
via the RGD motifs to release active TGF-β1, the LAP
DP is not produced (Wipff et al. 2007). Therefore com-
pared to integrins, PLK-cleaved R58 LAP-DP will serve
as a more direct biomarker for TGF-β1 activation and
following liver fibrosis.
Du X et al. showed that MMP-2 is related to renal fibrosis
(Du et al. 2012). Several MMPs are also known to activate
Figure 8 Immunostaining of biopsied human liver tissues. (a, d) Liver biopsy samples from four patients (chronic hepatitis B and C virus
infection [CH (B) and (C), respectively], AIH with severe fibrosis, and NASH. The hepatitis activity grade and fibrosis score are described in the
upper corresponding micrograms. (b) Serial sections from CH(C) patient were stained with R58 and L59 antibodies. (c) Liver specimens from
another CH(B) patient were stained with anti-αSMA, R58 antibodies. αSMA and R58 signal positive cells lined up along fibrous septa (yellow arrows).
Scale bars = 50 μm.
Figure 7 Detection of phosphorylated Smad3C in activated HSCs in CCl4-treated mice liver sections. Phosphorylation and nuclear
translocation of Smad3C in activated HSCs were examined by immunofluorescent double staining with anti-pSmad3C (red) and anti-αSMA (green)
antibodies. Nuclei of the cells were identified by Hoechst 33258 staining (blue). The pSmad3C positive-activated HSCs were seen only in
CCl4-treated mice. Scale bar = 50 μm.
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cleavage sites within LAP have not been determined.
Therefore, we are expanding our current method to de-
tect MMP-mediated TGF-β1 activation in the kidney.
Conclusions
In summary, we demonstrate here 1) PLK cleaves LAP be-
tween R58 and L59 residues, 2) PLK-dependent TGF-β acti-
vation occurs in human hepatic fibrosis, and 3) PLK-cleaved
LAP-DP is the potential surrogate marker for proteolytic
TGF-β1/3 activation and in turn fibrogenesis in the liver.
Methods
Materials
Recombinant human TGF-β1 LAP (rhLAP β1) and both
monoclonal and polyclonal anti-human LAP β1 antibodies
(MAB246 and AF246, respectively) were purchased from
R&D Systems (Minneapolis, MN). Human PLK was from
CalBiochem (San Diego, CA). Anti-αSMA antibody were
purchased from DAKO (Glostrup, DK). Anti-CD31 anti-
body was from dianova GmbH (Hamburg, DE). Anti-F4/
80 antibody was from AbD serotec, LLC (Oxford, UK).
Anti-pSmad3C polyclonal antibody was a kind gift from
Dr. Matsuzaki (Kansai Med. Univ., Japan). GST-rhLTGF-β1
protein was prepared as described follows. A plasmid
encoding GST-rhLTGF-β1 was constructed by insert-
ing a human TGF-β1 cDNA into the pGEX-6P-1 vector
(GE Healthcare, Buckinghamshire, UK), and protein
expressed in E. coli. BL21 (Stratagene, La Jolla, CA) and
purified using Glutathione Sepharose (GE Healthcare).
Determination of the cleavage sites within LAP by PLK
To identify the cleavage site in LAP during latent
TGF-β1 activation by PLK, rhLAP β1 was incubated
with PLK. After digestion, the resultant fragments were
separated by SDS-polyacrylamide gel electrophoresis,
and the N-terminal sequence of each LAP-DP was deter-
mined using a pulsed liquid protein sequencer Precise
494cLC (Hayashi et al. 2008).
Preparation of R58 and L59 monoclonal antibodies against
neo C- and N-termini of LAP-DPs generated by PLK
Murine R58 and L59 monoclonal antibodies were generated
against an 8 amino acid peptide, ending at R58 and plus
a CG linker sequence at its N-terminus [CGGQILSKLR
(Figure 1b)] and an 11 amino acid peptide, beginning from
L59 and plus a GGC linker sequence [LASPPSQGEVPGGC
(Figure 1b)]. BALB/c mice purchased from Charles River
Laboratories Japan, Inc. (Kanagawa, Japan) were immunized
with 50 μg of the antigen peptides. Once an appropriate
titer had been achieved, fusion was performed using a
protocol adapted from Lane et al. (Lane et al. 1986). Posi-
tive clones, which reacted to the BSA-conjugated antigen
peptide, but not to the terminus-modified antigen peptide(the C-termini were amidated for R58 antibody, while the
N termini were acetylated for L59 antibody production),
were selected. The antibodies were purified through the
Protein G column (GE Healthcare).
SDS-PAGE and Western blot analysis
GST-rhLTGF-β1 as well as rhLAP β1 were digested by co-
incubation with PLK or PLK at 37°C for 45 min. Thereafter,
equal amounts of samples containing either 50 ng of GST-
rhLTGF-β1 or 500 ng of rhLAP β1 were subjected to each
lane in SDS-PAGE under reducing conditions, followed by
transfer onto PVDF membrane (Millipore, Bedford, MA).
Western blot analyses were performed using either monoclo-
nal R58 and L59 antibodies (2 μg/ml) plus HRP-conjugated
anti-mouse antibodies (1:5,000) (Jackson Immuno Research
Laboratories, Inc., West Grove, PA) and reprobed either with
monoclonal or polyclonal anti-LAP antibodies. The bands
were visualized by a Western Blotting Substrate Plus
purchased from Thermo Scientific (Rockford, IL).
Animal models
Male C57BL/6 mice were purchased from Japan SLC Inc.
(Shizuoka, Japan). All animals were maintained on a 12 hour
light/12 hour dark cycle. Food and water were available
ad libitum. All animal experiments were performed in
accordance with protocols approved by the RIKEN
Institutional Animal Use and Care Administrative Advisory
Committee. For the CCl4-induced liver fibrosis model, mice
were injected intramuscularly with 50% CCl4 (CCl4: olive
oil = 1:1, 2 ml/kg) twice a week for 12 weeks. Control ani-
mals were injected with the same volume of olive oil. Mice
were sacrificed one week after the last CCl4 injection. For
the BDL model, ligation of the common bile duct was
performed according to Arias et al. (Arias et al. 2003).
Sham-operated mice were treated in the same manner
except that the bile duct was not ligated. The animals
were sacrificed at 14 days after operation.
Patient samples
The study was performed in accordance with the Declar-
ation of Helsinki and was approved by the Ethics Committee
for Biomedical Research of the Jikei University School of
Medicine and RIKEN Institute Research Ethics Committee.
All patients had signed a written informed consent prior to
study. Liver biopsy samples were taken from patients suf-
fering with cirrhotic liver diseases due to infection with
types B and/or C hepatitis virus, AIH and NASH.
The stage of fibrosis and the grade of inflammatory
activity were classified according to the METAVIR score
(Bedossa and Poynard 1996).
Staining of liver tissue sections
Animal tissue specimens were fixed in 4% paraformal-
dehyde, and human biopsied samples were fixed in 10%
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fin. Sections (4 μm thickness) were stained by Hematoxylin
and Eosin (HE), as well as 0.1% picro-sirius red solution for
diagnostic purposes. For immunostaining of the LAP-DP,
antigens were retrieved by microwave in citrate buffer
(pH 6), and thereafter sections were incubated in 0.3%
H2O2/methanol for 30 min to block endogenous perox-
idases, followed by incubation in phosphate buffered
saline with 0.1% Tween 20 (PBST) containing 5% skim
milk for 30 min to prevent nonspecific binding. Serial
sections were then incubated with R58 (1 μg/ml) or
L59 (1 μg/ml) overnight at 4°C. As negative controls,
slides were incubated with nonimmune IgG under the
same conditions. EnVision/HRP (DAKO) was used as
the second antibody. Serial sections were also immuno-
stained with anti-αSMA (diluted with 1:100, an activated
HSC marker), anti-CD31 (5 μg/ml, a liver sinusoidal endo-
thelial cell marker), and anti-F4/80 (5 μg/ml, a Kupffer cell
marker) antibodies. The sections were counterstained with
Hematoxylin. Fibrosis was detected using Sirius red as pre-
viously described (Junqueira et al. 1979). Both fibrotic areas
and R58 positive areas were measured in each of three
fields of five independent sections by WinROOF image
analysis software.
Immunofluorescent staining
Four μm of liver sections were deparaffinized and heated to
121°C in citrate buffer (pH6) by an autoclave for 10 min for
antigen retrieval. After blocking with 3% BSA/10% normal
goat serum/0.1 M glycine/PBST for 30 min, the sections
were incubated with both anti-pSmad3C (2 μg/ml) and
anti-αSMA (1:100) antibodies overnight at 4°C, followed by
incubation with both Alexa Fluor 488 anti-rabbit IgG and
Alexa Fluor 555 anti-mouse IgG (1:1000; red; Life Tech-
nologies, Carlsbad, CA) for 2 hours at room temperature.
Thereafter, the sections were incubated with Hoechst
33258 (1:5000, DOJINDO Laboratories, Kumamoto, Japan)
for 10 min at room temperature, and were mounted with
Fluoromount (Diagnostic BioSystems, Pleasanton, CA).
Image data were acquired on a Zeiss LSM 700 laser scan-
ning confocal microscopy.
Statistical analysis
Quantitative data are shown as mean ± SE. The two-sample
Wilcoxon rank-sum test was employed to evaluate differ-
ence between two groups. A p-value < 0.01 was considered
as statistically significant.Additional files
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